Clinical Review

Quality of Life in Patients With Atopic Dermatitis

Author and Disclosure Information

Atopic dermatitis (AD) is a chronic disease that impairs the patient’s quality of life (QOL) given its impact on sleep, work productivity, emotional and mental health, physical activity, and social functioning. In this review, the most important findings about QOL in AD are summarized. We also aim to demonstrate the most commonly used methods for measuring QOL and to give practical advice on using these instruments in clinical practice and research. Furthermore, AD puts a great burden on patients, and the degree of this burden is related to disease severity.

Practice Points

  • For assessing quality of life (QOL) in atopic dermatitis (AD), it is recommended that researchers use a combination of a generic and a dermatology-specific or AD-specific instrument, whereas clinicians should apply a dermatology-specific or an AD-specific method or both.
  • Anxiety and depression are common comorbidities in AD; patients also may need psychological support.
  • Patient education is key for improving QOL in AD.
  • Financial aspects of the treatment of AD should be taken into consideration because AD requires constant care, which puts a financial burden on patients.


 

References

Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease typically with childhood onset. In some cases, the condition persists, but AD usually resolves by the time a child reaches adulthood. Prevalence is difficult to estimate but, in developed countries, is approximately 15% to 30% among children and 2% to 10% among adults.1

Atopic dermatitis is characterized by chronically itchy dry skin, weeping erythematous papules and plaques, and lichenification. Furthermore, AD often is associated with other atopic diseases, such as food allergy, allergic rhinitis, and bronchial asthma.

In this article, we review the literature on the quality of life (QOL) of patients with AD. Our goals are to discuss the most common methods for measuring QOL in AD and how to use them; highlight specific alterations of QOL in AD; and review data about QOL of children with AD, which is underrepresented in the medical literature, as studies tend to focus on adults. In addition, we address the importance of assessing QOL in patients with AD due to the psychological burden of the disease.

Quality of Life

The harmful effects of AD can include a range of areas, including emotional and mental health, physical activity, social functioning, sleep disturbance, decreased work productivity, financial expenditure, leisure activities, and family relationships. The impact varies by age of the patient, and there are specific instruments for measuring QOL in infants, children, adolescents, and adults.

Because QOL is an important instrument used in many AD studies, we call attention to the work of the Harmonising Outcome Measures for Eczema (HOME) initiative, which established a core outcome set for all AD clinical trials to enable comparison of results of individual studies.2 Quality of life was identified in HOME as one of 4 basic outcome measures that should be included in every AD trial (the others are clinician-reported signs, patient-reported symptoms, and long-term control).3 According to the recent agreement, the following QOL instruments should be used: Dermatology Life Quality Index (DLQI) for adults, Children’s Dermatology Life Quality Index (CDLQI) for children, and Infants’ Dermatitis Quality of Life Index (IDQOL) for infants.4

In dermatology, these instruments can be divided into 3 basic categories: generic, dermatology specific, and disease specific.5 Generic QOL questionnaires are beneficial when comparing the QOL of an AD patient to patients with other conditions or to healthy individuals. On the other hand, dermatology-specific and AD-specific methods are more effective instruments for detecting impairments linked directly to the disease and, therefore, are more sensitive to changes in QOL.5 Some of the most frequently used QOL measures5,6 for AD along with their key attributes are listed in the Table.

Given that AD is a chronic disease that requires constant care, parents/guardians or the partner of the patient usually are affected as well. To detect this effect, the Family Dermatology Life Quality Index (FDLQI), a dermatology-specific instrument, measures the QOL in family members of dermatology patients.7 The Dermatitis Family Impact (DFI)8 is a disease-specific method for assessing how having a child with AD can impact the QOL of family members; it is a 10-item questionnaire completed by an adult family member. The FDLQI7 and DFI8 both help to understand the secondary impact of the disease.

Next Article: